BioSpace News Archive

Day One Biopharmaceuticals announced management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. ET.

Gain Therapeutics, Inc. presented new pre-clinical data from its Gaucher disease program in a poster presentation at the 19th Annual WORLDSymposium held February 22–26, 2023, in Orlando, Florida.

EyePoint Pharmaceuticals, Inc. announced that EyePoint Pharmaceuticals will present at the following upcoming conferences.

Amarin Corporation plc (NASDAQ:AMRN) today announced that data evaluating the role of VASCEPA®/VAZKEPA® (icosapent ethyl) and eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients will be presented at the joint ACC.23 together with the World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.

Levation Pharma Ltd., a pharmaceutical company focused on the development of new therapeutics for the ophthalmology and aesthetic space, received FDA clearance to initiate a Phase I/II of LEV102 for the treatment of Acquired Blepharoptosis in adults.

PDS Biotechnology Corporation announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration for a combination therapy of PDS0101, PDS0301 and an FDA-approved immune checkpoint inhibitor for the treatment of recurrent/metastatic human papilloma virus -positive, ICI refractory head and neck cancer.

Immuneering Corporation announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Monday, March 6 after the close of trading.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhney, M.D. to its Board of Directors.

Apexigen, Inc. today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.